FES PET/CT brain scans for breast cancer spread to the brain
Tests FES brain scans in breast cancer that reached the brain.
Key facts
- Who runs it
- Weill Medical College of Cornell University
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 20 people, planned
- Started
- 27 Dec 2023
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- Brain Imaging with 18F-FES
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with ER-positive breast cancer that has spread to the brain, who are planned for radiation to the brain. They will have an extra 18F-FES PET/CT brain scan.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Active ER+ breast cancer confirmed by biopsy, with new or returning brain metastases (cancer spread to the brain), proven by biopsy or suspected on MRI. Daily activity score (ECOG) 0-1. Expected to live at least 6 months.
- Earlier treatment
- ER modulators must be stopped for at least 8 weeks, and ER down regulators for at least 28 weeks. Radiation to the brain metastases must be planned.
- Biomarker or test result
- Estrogen receptor positive (ER+) breast cancer
Main reasons for not taking part
- Pregnancy
- Unable to have standard of care
- Allergy to FES
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Active diagnosis of ER+ breast cancer (biopsy proven) and new or recurrent brain metastases (biopsy proven or suspected based on MRI appearance)
- Ability to provide informed consent
- Discontinuation of ER modulators for at least 8 weeks, and discontinuation of ER down regulators for at least 28 weeks (as per manufacturer guidelines)
- Age >=18 years
- Eastern Cooperative Oncology Group performance score 0-1
- Life expectancy >=6 months
- Planned for radiation treatment for brain metastases
Who cannot take part
- Allergy to FES
- Pregnancy
- Unable to undergo Standard of Care
This trial is currently available in United States.
- New York - Presbyterian - Weill Cornell Medical CenterNew York, United StatesContact: Jana Ivanidze, MD/PhDTaking people
About the trial
What the trial wants to find out
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 months.
Read full original descriptionShow less
Study Population: Patients with ER-positive breast cancer with biopsy proven or suspected new or recurrent brain metastases (based on standard of care MRI) planned for radiation treatment of brain lesions.
The group in the trial
- ER Positive Breast Cancer Patients with Brain MetastasesTreatment being tested
A diagnostic intervention where this group will undergo an additional 18F- FES PET/CT scan in addition to their standard of care MRI and FDG PET/CT scan.
Treatment: Brain Imaging with 18F-FES
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Brain [18F]-FES PET/CT in the Diagnosis, Treatment Planning and Response Assessment of Brain Metastases in Patients With Estrogen-Receptor Positive Breast Cancer
- Plain-language title
- FES PET/CT brain scans for breast cancer spread to the brainGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 29 October 2026